Citigroup
APUS icon

Citigroup’s Apimeds Pharmaceuticals US APUS Stock Holding History

Citigroup’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5 Buy
+1
New +$5 ﹤0.01% 5862

Other funds holding APUS

HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Hemenway Trust Hemenway Trust
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.42B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Ankerstar Wealth
Ankerstar Wealth Leander, Texas $129M AUM 9.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Citigroup's APUS Position: Q3 2026 in Review

Citigroup opened a new position in Apimeds Pharmaceuticals US (APUS) in Q3 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #5862 among its holdings.

8 funds tracked by Wall St. Rank hold APUS as of Q3 2026.

  • Citigroup held 1 share of Apimeds Pharmaceuticals US worth $5 as of Q3 2026.
  • Apimeds Pharmaceuticals US was a new Citigroup position in Q3 2026.
  • Apimeds Pharmaceuticals US made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5862 holding.
  • 8 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.